Fibromuscular dysplasia natural history, complications and prognosis
|
Fibromuscular dysplasia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
ASA/ACCF/AHA Guideline Recommendations |
|
Management of Patients With Fibromuscular Dysplasia of the Extracranial Carotid Arteries |
|
Case Studies |
|
Fibromuscular dysplasia natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Fibromuscular dysplasia natural history, complications and prognosis |
|
FDA on Fibromuscular dysplasia natural history, complications and prognosis |
|
CDC on Fibromuscular dysplasia natural history, complications and prognosis |
|
Fibromuscular dysplasia natural history, complications and prognosis in the news |
|
Blogs on Fibromuscular dysplasia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Since Fibromuscular dysplasia can involve virtually every artery of the body, thus the clinical presentations of FMD vary widely and are determined by the vessels territories that are involved. in the FMD, multivessel involvement is common,then numerous and various manifestation may present. The clinical presentations of FMD may result from the stenosis, ischemia, dissection and occlusion,rupture of aneurysms and embolization of intravascular thrombi from dissection or aneurysms.[1][2]
Natural History, Complications, and Prognosis
Natural History
Complications
- Common complications of [disease name] include:
- [Complication 1]
- [Complication 2]
- [Complication 3]
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
- Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Jeffrey W. Olin & Brett A. Sealove (2011). "Diagnosis, management, and future developments of fibromuscular dysplasia". Journal of vascular surgery. 53 (3): 826–836. doi:10.1016/j.jvs.2010.10.066. PMID 021236620. Unknown parameter
|month=ignored (help) - ↑ Jeffrey W. Olin, Heather L. Gornik, J. Michael Bacharach, Jose Biller, Lawrence J. Fine, Bruce H. Gray, William A. Gray, Rishi Gupta, Naomi M. Hamburg, Barry T. Katzen, Robert A. Lookstein, Alan B. Lumsden, Jane W. Newburger, Tatjana Rundek, C. John Sperati & James C. Stanley (2014). "Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association". Circulation. 129 (9): 1048–1078. doi:10.1161/01.cir.0000442577.96802.8c. PMID 24548843. Unknown parameter
|month=ignored (help)